To test the potential of such novel siRNA delivery system in tumor therapy, we further investigated this h-R3-mediated siRNA delivery system, compared with dendriplex, HSA-dendriplex and EGF-dendriplex, in PLK1-siRNA (siPLK1) delivery against HepG2 cells and tested the efficacy, including gene silencing, cell growth inhibition, cell apoptosis and cellular migration/invasion. This evidence concerns the gene ALB and neoplasm.